Engineered immune cells take on recurrent ovarian cancer in new trial
NCT ID NCT05601752
First seen Mar 01, 2026 · Last updated May 16, 2026 · Updated 8 times
Summary
This phase 2 study tests a personalized cell therapy (ADP-A2M4CD8) alone or with another drug (nivolumab) in 66 people with recurrent ovarian cancer. Only patients with certain genetic markers (HLA-A*02 and MAGE-A4) can join. The goal is to see if the treatment shrinks tumors and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Centre Leon-Berard
Lyon, 69008, France
-
Centro Oncologico Clara Campal
Madrid, 28050, Spain
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Honor Health
Scottsdale, Arizona, 85258, United States
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Hospotal Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Institut de Cancerologie de Strasbourg
Strasbourg, 67200, France
-
Institut de Cancerologie des Hospices Civils de Lyon
Pierre-Bénite, Lyon, 69310, France
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey, 08901, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
The Christie Hospital
Manchester, M20 4GJ, United Kingdom
-
University College of London Hospital
London, NW1 2PG, United Kingdom
-
University Health Network (Princess Margaret Cancer Center)
Toronto, Ontario, M5G 2M9, Canada
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
Vall d'Hebron Unversity Hospital
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.